Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
— CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 —
— CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 —
Related news for (CRBU)
- Today’s Top Performers: MoBot’s Market Review 06/06/25 07:00 PM
- MoBot’s Stock Market Highlights – 06/06/25 06:00 PM
- MoBot alert highlights: NASDAQ: ORGO, NASDAQ: NMRA, NASDAQ: CRBU, NASDAQ: GORV, NYSE: ACHR (06/06/25 05:00 PM)
- Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
- Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025